A parallel group, single-blind, randomised, placebo controlled study to evaluate the safety, tolerability and pharmacokinetics of GW823296 [orvepitant] and its effect on the pharmacokinetics of midazolam after once-daily repeated oral doses in healthy subjects.
Phase of Trial: Phase I
Latest Information Update: 07 Aug 2017
At a glance
- Drugs Orvepitant
- Indications Anxiety disorders; Major depressive disorder; Post-traumatic stress disorders
- Focus Adverse reactions
- Sponsors GlaxoSmithKline
- 24 Apr 2008 Status changed from recruiting to completed, reported by ClinicalTrials.gov.
- 22 Aug 2007 New trial record.